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Dietary supplementation with nutrients enhancing immune function is beneficial 
in patients with surgical and critical illness. Malnutrition and immune dysfunction 
are common features in hospitalized patients. Specific nutrients with immunologi-
cal and pharmacological effects, when consumed in amounts above the daily re-
quirement, are referred to as immune-enhancing nutrients or immunonutrients. 
Supplementation of immunonutrients is important especially for patients with im-
munodeficiency, virus or overwhelming infections accompanied by a state of mal-
nutrition. Representative immunonutrients are arginine, omega-3 fatty acids, gluta-
mine, nucleotides, beta-carotene, and/or branched-chain amino acids. Glutamine is 
the most abundant amino acid and performs multiple roles in human body. How-
ever, glutamine is depleted from muscle stores during severe metabolic stress in-
cluding sepsis and major surgery. Therefore it is considered conditionally essential 
under these conditions. This review discusses the physiological role of glutamine, 
mode and dose for glutamine administration, as well as improvement of certain 
disease state after glutamine supplementation. Even though immunonutrition has 
not been widely assimilated by clinicians other than nutritionists, immunonutrients 
including glutamine may exert beneficial influence on diverse patient populations.
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INTRODUCTION
A number of clinical studies have investigated the beneficial effects of enteral1,2 or 
parenteral3,4 nutrition after surgery, trauma, infection, starvation, or injury. Even 
though the mechanisms by which nutrients improve certain disease states have not 
yet been clarified, reduction of morbidity and shorter length of stay in septic pa-
tients,5 as well as reduced wound infection in burn patients6 were demonstrated af-
ter enteral feeding of nutrients. Critically ill patients who received the immune for-
mula had more rapid restoration of lymphocyte mitogenesis, reduction in infectious 
complications, and reduced mortality than those who did not.7 Therefore, clinicians 
and nutritionists have focused on the composition of the nutrient mix. Arginine 
and omega-3 fatty acids with or without glutamine, nucleotides, beta-carotene, and/
or branched-chain amino acids are important nutrients in the formula.8 They are re-
ferred to as immune-enhancing nutrients. The term “immunonutrition” has been Glutamine as an Immunonutrient
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beneficial effects for reducing symptoms of inflammatory 
disorders and may protect against the damaging effect of 
oxidative stress. Although glutamine is an important sub-
strate for glutathione, its capacity to synthesize glutathione 
is influenced by the presence of cysteine and glycine. The 
supply of sulfur-containing amino acids that can be con-
verted to cysteine is also important point to be considered 
for glutamine supplementation. 
Intestinal mucosal integrity and immune function
Glutamine has an important role in cell-mediated immuni-
ty21 and the integrity of the intestinal mucosa.22 During severe 
metabolic stress (i.e., trauma, sepsis, major surgery, bone 
marrow transplant, chemotherapy and radiotherapy), gluta-
mine stores are depleted.1-3,23-29 Glutamine supplementation 
during illness increases gut barrier and lymphocyte func-
tion and preserves lean body mass. Glutamine protects 
against septic shock by preventing the depletion of glutathi-
one and thus reducing cell death, which occurs during 
shock.30 In surgical or cancer patients, glutamine supple-
mentation decreases the production of some pro-inflamma-
tory cytokines31,32 which may be associated with inhibition 
of nuclear factor-κB and p38 mitogen-activated protein ki-
nase in the intestinal mucosa by glutamine supplementation 
to Crohn’s patients.33 
Expression of heat shock protein
Heat shock protein plays a role in tissue protection after 
stress or injury, as its absence leads to an increase in cellu-
lar apoptosis. Glutamine induces expression of heat shock 
protein and reduces expression of inflammatory cytokines.34 
The effect of glutamine on the induction of heat shock pro-
tein may be related to the beneficial effects of glutamine 
supplementation, such as a decrease in length of hospital 
stay and ventilator time in critically ill patients.35 
Conversion to arginine and reduction in insulin 
resistance
Glutamine is an important precursor for arginine through 
interorgan transport of citrulline.36,37 In addition, glutamine 
reduces insulin resistance.38
Down-regulation of Toll-like receptor 4 (TLR4)
When the cells are exposed to lipopolysacharide, expres-
sion of TLR4 and signal adaptor protein MyD88 are up-
regulated, which leads to the induction of inflammatory cy-
tokines such as TNF-α, IL-1 and IL-6 and intestinal mucosal 
based on the concept that malnutrition impairs immune 
function.9 In immunonutrition, supranormal quantities of 
nutrients are supplied to achieve pharmacological effects 
via the enteral or parenteral route.10 
In this review, one single nutrient, glutamine, is to be dis-
cussed, as it was previously omitted from most enteral feed-
ing and all parenteral infusions. This may have been due to 
the fact that glutamine is abundant in the body and is thus 
not an essential amino acid. In addition, the solubility of glu-
tamine is low in an aqueous environment, which makes glu-
tamine inappropriate for enteral and parenteral nutrition. 
During catabolic stress (trauma, sepsis, burn), glutamine is 
rapidly released from muscle stores and serum, and intracel-
lular levels of glutamine decrease.11-13 Therefore, glutamine 
becomes conditionally essential under these conditions.14 
This review discusses whether the glutamine supplementing 
enhances the physiologic and immunologic functions of 
critically ill patients by summarizing the role of glutamine 
in the human body, types and doses of glutamine supple-
mentation, and changes in disease states after glutamine ad-
ministration.
PHYSIOLOGICAL ROLE
 
Glutamine provides fuel for rapidly dividing cells (particu-
larly lymphocytes and enterocytes)11 as well as the epitheli-
al cells of the intestines.15 Glutamine maintains gut barrier 
function, and is a precursor for the endogenous antioxidant 
glutathione.10  It plays an important role in nitrogen trans-
port within the body, and serves as a substrate for renal am-
moniagenesis.16 Glutamine induces the expression of heat 
shock proteins and stimulates nucleotide synthesis.17 Sig-
naling mediators such as extracellular signal-regulated pro-
tein kinases that regulate cell differentiation are activated 
by glutamine.18 Glutamine contributes to mucin formation 
and intestinal surface integrity by mediating the synthesis 
of N-acetylglucosamine and N-acetylgalactosamine.19  
Precursor for glutathione 
Concentrations of glutathione are suboptimal in clinical con-
ditions including HIV infection, hepatitis C infection, cirrho-
sis, type II diabetes, ulcerative colitis, and myocardial infarc-
tion. Three amino acids are needed to synthesize glutathione: 
glycine, glutamic acid and cysteine. Glutamine is easily con-
verted to glutamic acid and produces an antioxidant glutathi-
one.20 Therefore, supplementation of glutamine may have Hyeyoung Kim
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overall incidence of necrotizing enterocolitis/septicemia in 
preterm infants.47 Administration of enteral nutrition with a 
glutamine enriched formula (30.5 g/100 g protein feeding) 
resulted in a significant decrease in the incidence of pneu-
monia, bacteremia, and sepsis of critically ill patients as com-
pared to control feeding (3.5 g/100 g protein).48 Intravenous 
infusion of glutamine dipeptide as L-alanyl-glutamine 
(0.285 g/kg body weight/day) reduced the rate of mortality 
in critically ill patients.49 Glutamine (0.4 g/kg body weight/
day)-supplemented total parenteral nutrition significantly 
decreases leukocyte and natural killer cell count and there-
fore suppresses inflammation in patients with systemic in-
flammatory response syndrome.50
DISEASE STATE AFTER 
SUPPLEMENTATION 
Severity of illness in patients in the intensive care unit 
(ICU) and septic patients
Patients in the ICU have low plasma glutamine concentra-
tions (<0.42 mmol/L) at the time of admission, which may 
be related to the severity of their illness and high mortality 
rate.51 Glutamine supplementation reduced infection and in-
flammation in critically ill patients, but the length of stay 
was not changed by glutamine supplementation.10 In surgi-
cal or critically ill patients, the addition of glutamine re-
duced infection rates and shortened the length of hospital 
stay, but had no effect on mortality.52 Although it is contro-
versial as to whether glutamine supplementation reduces 
mortality or length of hospitalization in patients in the ICU 
and critically ill patients, supplementation does decrease 
their rate of infection and inflammation. 
Patients undergoing chemotherapy and patients 
following hematopietic stem cell transplantation
Enteral feeding of glutamine reduced mucositis in chemo-
therapy patients28 and in head and neck cancer patients with 
radiotheraphy.29 Total parenteral nutrition with glutamine 
reduced the severity and duration of mucositis, and the du-
ration of hospitalization for bone marrow transplant pa-
tients.26,53 Glutamine dipeptide-supplemented total parenter-
al nutrition had no effect on neutropenic period, fever, extra 
antibiotics, or toxicity scores, but body weight gain per treat-
ment cycle in catabolic hematologic patients with intensive 
chemotherapy.27 Even though glutamine showed positive 
effects on mucositis of the gastrointestinal tract caused by 
injury.39 Enteral feeding of glutamine reduces the induction 
of TLR4, MyD88 and TRAF6 mRNA, and suppresses in-
jury to the mucous membrane of the small intestines caused 
by LPS endotoxemia in rats.40 Glutamine induced down-
regulation of TLR4 expression in intestinal epithelial cells 
infected with gram-negative bacteria.41 TLR4-dependent 
immune response and anti-bacterial/anti-inflammatory re-
sponse after glutamine supplementation were reported in 
septic patients.5
MODE AND DOSE OF 
SUPPLEMENTATION
 
Glutamine dipeptide as a supplement 
To overcome the low stability of glutamine in an aqueous 
environment, glutamine coupled with other amino acid 
(glycine or alanine) has been developed as a component of 
nutrient mix. Glutamine couples with alanine or glycine to 
form a less degradable dipeptide.42 Both L-Glutamine and 
L-alanyl-L-glutamine prevented oxidant- or endotoxin-in-
duced death of neonatal enterocytes in vitro.43
In humans, arterial glutamine concentrations were better 
after parenteral administration of alanyl-glutamine than af-
ter administration of free glutamine.44 Peritonitis patients 
who received a solution containing L-alanyl-L-glutamine 
had lower mortality rates than those who received nutrition 
that did not.45 
Dry-packing of glutamine and proteins rich in 
glutamine
Glutamine is easily degraded in a solution into a toxic prod-
uct-pyroglutamate-particularly during heat sterilization. 
Therefore, formulas with free glutamine amino acids are 
packaged dry and reconstituted just prior to administration. 
Proteins rich in glutamine could be used as a glutamine 
supplement to avoid toxicity issues in prepared liquid for-
mulas.8 A recent study showed that an arginine-supplement-
ed immune enhancing diet increased plasma glutamine, 
possibly by enhancing de novo synthesis of glutamine from 
arginine in post-operative patients.46 Interaction/inter-con-
version of amino acids and nutrients is an important re-
search field to be resolved in immunonutrition.
Doses of glutamine
Oral glutamine (0.3 g/kg body weight/day) administration 
showed beneficial effects on intestinal integrity and the Glutamine as an Immunonutrient
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prior to supplementation of immunonutrients including glu-
tamine. Immunonutrition may be potentially useful as a ther-
apeutic modality with close communication and information 
exchange between clinicians and nutrition specialists.
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